Literature DB >> 33946181

Significance of TERT Genetic Alterations and Telomere Length in Hepatocellular Carcinoma.

Jeong-Won Jang1,2, Jin-Seoub Kim2, Hye-Seon Kim2, Kwon-Yong Tak1,2, Soon-Kyu Lee1,2, Hee-Chul Nam1,2, Pil-Soo Sung1,2, Chang-Min Kim3, Jin-Young Park3, Si-Hyun Bae1,2, Jong-Young Choi1,2, Seung-Kew Yoon1,2.   

Abstract

Telomerase reverse transcriptase (TERT) mutations are reportedly the most frequent somatic genetic alterations in hepatocellular carcinoma (HCC). An integrative analysis of TERT-telomere signaling during hepatocarcinogenesis is lacking. This study aimed to investigate the clinicopathological association and prognostic value of TERT gene alterations and telomere length in HCC patients undergoing hepatectomy as well as transarterial chemotherapy (TACE). TERT promoter mutation, expression, and telomere length were analyzed by Sanger sequencing and real-time PCR in 305 tissue samples. Protein-protein interaction (PPI) analysis was performed to identify a set of genes that physically interact with TERT. The PPI analysis identified eight key TERT-interacting genes, namely CCT5, TUBA1B, mTOR, RPS6KB1, AKT1, WHAZ, YWHAQ, and TERT. Among these, TERT was the most strongly differentially expressed gene. TERT promoter mutations were more frequent, TERT expression was significantly higher, and telomere length was longer in tumors versus non-tumors. TERT promoter mutations were most frequent in HCV-related HCCs and less frequent in HBV-related HCCs. TERT promoter mutations were associated with higher TERT levels and longer telomere length and were an independent predictor of worse overall survival after hepatectomy. TERT expression was positively correlated with tumor differentiation and stage progression, and independently predicted shorter time to progression after TACE. The TERT-telomere network may have a crucial role in the development and progression of HCC. TERT-telomere abnormalities might serve as useful biomarkers for HCC, but the prognostic values may differ with tumor characteristics and treatment.

Entities:  

Keywords:  TERT; biomarkers; liver neoplasm; telomere; treatment outcome

Year:  2021        PMID: 33946181     DOI: 10.3390/cancers13092160

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  21 in total

1.  Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.

Authors:  Dong-Sheng Huang; Zhaohui Wang; Xu-Jun He; Bill H Diplas; Rui Yang; Patrick J Killela; Qun Meng; Zai-Yuan Ye; Wei Wang; Xiao-Ting Jiang; Li Xu; Xiang-Lei He; Zhong-Sheng Zhao; Wen-Juan Xu; Hui-Ju Wang; Ying-Yu Ma; Ying-Jie Xia; Li Li; Ru-Xuan Zhang; Tao Jin; Zhong-Kuo Zhao; Ji Xu; Sheng Yu; Fang Wu; Junbo Liang; Sizhen Wang; Yuchen Jiao; Hai Yan; Hou-Quan Tao
Journal:  Eur J Cancer       Date:  2015-04-02       Impact factor: 9.162

2.  Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.

Authors:  Jean Charles Nault; Julien Calderaro; Luca Di Tommaso; Charles Balabaud; Elie Serge Zafrani; Paulette Bioulac-Sage; Massimo Roncalli; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

3.  Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice.

Authors:  S E Artandi; S Chang; S L Lee; S Alson; G J Gottlieb; L Chin; R A DePinho
Journal:  Nature       Date:  2000-08-10       Impact factor: 49.962

4.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

5.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

6.  Telomerase: central regulator of all of the hallmarks of cancer.

Authors:  Kee Chung Low; Vinay Tergaonkar
Journal:  Trends Biochem Sci       Date:  2013-08-07       Impact factor: 13.807

7.  Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.

Authors:  Fukiko Kawai-Kitahata; Yasuhiro Asahina; Shinji Tanaka; Sei Kakinuma; Miyako Murakawa; Sayuri Nitta; Takako Watanabe; Satoshi Otani; Miki Taniguchi; Fumio Goto; Hiroko Nagata; Shun Kaneko; Megumi Tasaka-Fujita; Yuki Nishimura-Sakurai; Seishin Azuma; Yasuhiro Itsui; Mina Nakagawa; Minoru Tanabe; Shinichi Takano; Mitsuharu Fukasawa; Minoru Sakamoto; Shinya Maekawa; Nobuyuki Enomoto; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2015-11-09       Impact factor: 7.527

8.  Cause-specific telomere factors deregulation in hepatocellular carcinoma.

Authors:  Manale El Idrissi; Valérie Hervieu; Philippe Merle; Franck Mortreux; Eric Wattel
Journal:  J Exp Clin Cancer Res       Date:  2013-09-11

9.  Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.

Authors:  Hye Won Lee; Tae In Park; Se Young Jang; Soo Young Park; Won-Jin Park; Soo-Jung Jung; Jae-Ho Lee
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

10.  A Nine-Gene Signature for Predicting the Response to Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer.

Authors:  In Ja Park; Yun Suk Yu; Bilal Mustafa; Jin Young Park; Yong Bae Seo; Gun-Do Kim; Jinpyo Kim; Chang Min Kim; Hyun Deok Noh; Seung-Mo Hong; Yeon Wook Kim; Mi-Ju Kim; Adnan Ahmad Ansari; Luigi Buonaguro; Sung-Min Ahn; Chang-Sik Yu
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

View more
  3 in total

1.  Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma.

Authors:  Yulan Zhao; Ting Huang; Pintong Huang
Journal:  Diagnostics (Basel)       Date:  2022-08-08

Review 2.  DNA and RNA Binding Proteins: From Motifs to Roles in Cancer.

Authors:  Ondrej Bonczek; Lixiao Wang; Sivakumar Vadivel Gnanasundram; Sa Chen; Lucia Haronikova; Filip Zavadil-Kokas; Borivoj Vojtesek
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

Review 3.  Virus-Driven Carcinogenesis.

Authors:  Yuichiro Hatano; Takayasu Ideta; Akihiro Hirata; Kayoko Hatano; Hiroyuki Tomita; Hideshi Okada; Masahito Shimizu; Takuji Tanaka; Akira Hara
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.